Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone

Bibliography

• DZAU V, PACKER M, LILLY L et al.: Prostaglandins in se-vere congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. New Engl. J. Med. (1984) 310:347–352.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY: Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Sur-vival Study (Consensus). New Engl. J. Med. (1987) 55:3–8.
   Google Scholar
• SOLVD INVESTIGATORS: Effects of enalapril on survival in patients with reduced left ventricular ejection frac-tion and congestive heart failure. New Engl. J. Med. (1991) 295:293–302.
   Google Scholar
• COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl. J. Med. (1991) 325:303–310.
   PubMed Web of Science ®Google Scholar
• STRUTHERS A: Aldosterone escape during angiotensin converting enzyme inhibition therapy in chronic heart failure. J. Card. Fail. (1996) 2:47–54.
   PubMedGoogle Scholar
• YUSEF S, MAGGIONI A, HELD P etal.: Effects of candesar-tan, enalapril or their combination on exercise capac-ity, ventricular function, clinical deterioration, and quality of life in heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RE-SOLVD). Circulation (1997) 96:1452. (Abstract).
   Google Scholar
• HENSEN J, ABRAHAM J, DURR A et al: Aldosterone incongestive heart failure: analysis of determinants and role in sodium retention. Am. J. Nephrol. (1991) 11:441–446.
   PubMed Web of Science ®Google Scholar
• STRUTHERS A: Mineralocorticoid receptor blockade inchronic heart failure. J. Hum. Hypertens. (1995) 9:443–446.
   PubMed Web of Science ®Google Scholar
• FUNDER J, FELDMAN D, EDELMAN I: Specific aldoster-one binding in rat kidney and parotid. J. Steroid Bio-chem. (1972) 3:209–218.
   PubMedGoogle Scholar
• ANDERSON N, FANESTIL D: Corticoid receptors in rat brain: evidence for an aldosterone receptor. Endocri-nology (1976) 98:676.
   PubMed Web of Science ®Google Scholar
• DENICOLA A, TRONELLO S, WEISENBERG L, FRIDMAN 0, BIRMINGHAM M: Uptake and binding of (113) aldoster-one to the anteriopituitary and brain regions in ad-renalectomized rats. Horm. Metab. Res. (1981) 13:103.
   PubMed Web of Science ®Google Scholar
• PEARCE P, FUNDER J: High affinity aldosterone binding sites (type I receptors) in rat heart. Clin. Exp. Pharma-col. Physiol (1987) 14:859–866.
   PubMed Web of Science ®Google Scholar
• LOMBES M, OBLIN M, GASC J et al: Immunohistochemi-cal and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ. Res. (1992) 71:503–510.
   PubMed Web of Science ®Google Scholar
• YOUNG M, FUNDER J: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am. J. Physiol (1996) 271:E883–E888.
   Google Scholar
• FUNDER J: Aldosterone action. Ann. Rev. Physiol (1993) 55:115–130.
   PubMed Web of Science ®Google Scholar
• ZANNAD F: Aldosterone and heart failure. Eur. Heart J. (1995) 16:98–102.
   PubMed Web of Science ®Google Scholar
• WEBER K, VELLARREAL D: Role of aldosterone in con-gestive heart failure. Postgrad. Med. (1993) 93:203–221.
   PubMed Web of Science ®Google Scholar
• SHEEHAN J, SEELIG M: Interaction of magnesium and potassium in the pathogenesis of cardiovascular dis-ease. Magnesium (1984) 3:301–314.
   PubMedGoogle Scholar
• DYCKNER T: Relationship of cardiovascular disease to potassium and magnesium deficiencies. Am. J. Cardiol (1990) 65:44–68.
   Web of Science ®Google Scholar
• SISCOVICK D, RAGHUNATHAN T, PSATY B et al.: Diuretic therapy for hypertension and the risk of primary car-diac arrest. New Eng]. J. Med. (1994) 330:1852–1857.
   PubMed Web of Science ®Google Scholar
• WEHLING M, CHRIST M, THEISEN K: High affinity al-dosterone binding to plasma membrane rich fractions from mononuclear leukocytes: is there a membrane receptor for mineralocorticoids? Biochem. Biophys. Res. Commun. (1991) 181:1306–1312.
   PubMed Web of Science ®Google Scholar
• WEHLING M, KASMAYR J, THEISEN K: Fast effects of al-dosterone on electrolyte in human lymphocytes are mediated by the sodium-proton-exchanger of the cell membrane. Biochem. Biophys. Res. Commun. (1989) 164:961–967.
   PubMedGoogle Scholar
• MOURA A, WORCEL M: Direct action of aldosterone on transmembrane Na ± efflux from arterial smooth mus-cle. Hypertension (1984) 6:425–430.
   PubMed Web of Science ®Google Scholar
• ARORA R, SOMARI P: Ectopic arrhythmia provoking ac-tion of aldosterone. Life Sci. (1962) 5:215–218.
   Google Scholar
• BRILLA C, WEBER C: Reactive and reparative myocar-dial fibrosis in arterial hypertension in the rat. Cardio-vasc. Res. (1992) 26:671–677.
   PubMed Web of Science ®Google Scholar
• YOUNG M, FUNDER J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol (1995) 269:E657–E662.
   Google Scholar
• BRILLA C, ZHOU G, MATSUBARA L, WEBER K: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell Cardiol (1994) 26:809–820.
   PubMed Web of Science ®Google Scholar
• FULLERTON M, FUNDER J: Aldosterone and cardiac fi-brosis: in vitro studies. Cardiovasc. Res. (1994) 28:1863–1867.
   PubMed Web of Science ®Google Scholar
• ARAKI T, MASAMI S, HIROYUKI Y et al: Effects ofangiotensin-converting enzyme inhibitor and al-dosterone antagonist on myocardial collagen in car-diomyopathic hamsters. Jpn. Circ. 1 (1995) 59:213-218.
   Google Scholar
• MIKAMI H, KATAHIRA K, OGIHARA T et al.: Potentiationof the pressor effect of angiotensin II by intraventricu-lar infusion of hypertonic saline. Am. J. Hypertens. (1988) 1:4s–7s.
   Google Scholar
• TADDEI S, VIRDIS A, MATTEI P, SALVETTI A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension (1993) 21:929–933.
   PubMed Web of Science ®Google Scholar
• SAITO Y, NAKAO K, ARAI H et al.: Inhibition of aldoster-one biosynthesis by 18-ethynyl-deoxycorticosterone. Endocrinology (1991) 129:2361–2366.
   PubMed Web of Science ®Google Scholar
• KAGAWA C, CELLA J, VAN ARMAN C: Action of new ster-oids in blocking effects of blocking aldosterone and deoxycorticosterone on salt. Science (1957) 126:1015.
   PubMed Web of Science ®Google Scholar
• SADEE W, ABSHEGEN U, FINN C, RIETBROCK N: Conver-sion of spironolactone to canrenoate and disposition kinetics of spironolactone and cantenoate-potassium in rats. Naunyn Schmiedebergs Arch. Pharmacol. (1974) 283:303.
   PubMed Web of Science ®Google Scholar
• SADEE W, RIEGELMAN S, JONES S: Disposition of tritium-labeled spironolactone in the dog. J. Pharm. (1972) 61:1132.
   PubMed Web of Science ®Google Scholar
• SADEE W, RIEGELMAN S, JONES S: Plasma levels of spi-ronolactone in the dog. J. Pharm. Sci. (1972) 61:1129.
   PubMed Web of Science ®Google Scholar
• SADEE W, DAGCIOGLU M, SCHRODER R: Pharmacoki-netics of spironolactone, canrenone, and canrenenoate-K in humans. J. Pharmacol Exp. Ther. (1973) 185:686.
   PubMed Web of Science ®Google Scholar
• KARIM A, ZAGARELLA J, HUTSELL T, DOLLEY M: Spirono-lactone III. Canrenone-maximum and minimum steady-state plasma levels. Clin. Pharmacol Ther. (1976) 19:177.
   Google Scholar
• SADEE W, SCHRODER R, LEITNER V, DAGCIOGLY M: Mul-tiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure. Eur. J. Clin. Pharmacol. (1974) 7:195.
   PubMed Web of Science ®Google Scholar
• KARIM A, RANNEY R, MAIBACH H: Pharmacokinetics and metabolic fate of potassium canrenoate in man. J. Pharm. Sci. (1971) 60:708.
   PubMed Web of Science ®Google Scholar
• KARIM A, ZAGARELLA J, JRIBAR J, DOOLEY M: Spirono-lactone I. Disposition and metabolism. Clin. Pharma-col. Ther. (1976) 19:158.
   PubMed Web of Science ®Google Scholar
• HOFMAN L, DUTT M, DEYSACH L, LONCIN H, TAO L: Comparison of spironolactone tablet dosage forms in healthy humans. J. Pharm. Sci. (1974) 63:1248.
   PubMed Web of Science ®Google Scholar
• CHIEN Y, HOFMANN L, LAMBERT H, TAO L: Binding of spironolactone to human plasma proteins. J. Pharm. Sci. (1976) 65:1337.
   PubMed Web of Science ®Google Scholar
• ERBLER H, WERNZE H, HILFENHAUS M: Effect of the al-dosterone antagonist canrenone on plasma aldoster-one concentrations and plasma renin activity, and on the excretion of aldosterone and electrolytes by man. Eur. J. Clin. Pharmacol (1976) 9:253.
   PubMed Web of Science ®Google Scholar
• HENSEN J, WILLIAM T, ABRAHAM J, DURR J, SCHRIER R: Aldosterone in congestive heart failure: analysis of de-terminants and role in sodium retention. Am. J. Neph-rol. (1991) 11:441-446. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(5)
   Google Scholar
• BARR C, LANG C, HANSON J et al: Effects of adding spi- ronolactone to an angiotensin-converting enzyme in-hibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol (1995) 76:1259–1265.
   PubMed Web of Science ®Google Scholar
• BAYLISS J, NORELL M, CANEPA-ANSON R et al.: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br. Heart 1 (1987) 57:17–22.
   Google Scholar
• PELTOLA P, LAHOVAARA S, PAASONEN M: Effect of fu-roesmide and hydrochlorothiazide on plasma renin activity in man. Ann. Med. Exp. Biol. Fenn. (1970) 48:122–124.
   PubMedGoogle Scholar
• SCHOHN D, SPIESSER R, WEHRLEN M et al: Aldac-tazide/captopril combination, safe and effective in mild and moderate systemic hypertension: report on a multicenter study of 967 patients. Am. J. Cardiol (1990) 65:4-6K.
   Google Scholar
• THE RALES INVESTIGATORS (1996): Effectiveness of spi-ronolactone added to an ACE inhibitor and a loop diu-retic for severe chronic congestive heart failure. Am. J. Cardiol. (1996) 78:902–907.
   Google Scholar
• DE GASPARO M, JOSS U, RAMJOUE S et al: Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. (1987) 240:650–656.
   PubMed Web of Science ®Google Scholar
• DELYANI J, MYLES K, FUNDER J: Eplerenone (SC-66110), a highly selective aldosterone antagonist. Am. J. Hyper-tens. (In Press.)
   Google Scholar
• FRIERDICH G, SCHUH J, BROWN M et al: Effects of the se-lective mineralocorticoid receptor antagonist, eplere-none, in a model of aldosterone-induced hypertension and cardiac fibrosis. Am. J. Hypertens. (In Press.)
   Google Scholar